DUBLIN--(BUSINESS WIRE)--The "Pharmaceutical Export Market in India" report has been added to ResearchAndMarkets.com's offering.
The Indian Pharmaceutical exports market grew by 11.88% between FY 2019 and FY 2022 to reach INR 1,445.81 Bn in FY 2022, despite the global pharmaceutical industry shrinking by 1-2% in 2020 due to COVID-19. This was despite the global industry reduced by almost 2% in 2020 on account of COVID-19.
Market insights:
The pharmaceutical industry has witnessed rapid growth in the past few decades and is expected to develop further, owing to huge export possibilities. The business caters to 50% of the global demand of various vaccines, 40% of generic medicines demand in the US, and 25% of all medication in the UK.
Impact of COVID-19:
The onslaught of COVID-19 and the nationwide lockdown severely impacted the healthcare and pharmaceutical infrastructure, and the country's economy. Travel restrictions, shortage of workforce, disruption in world trade, and bottleneck in logistics impacted the supply chain of pharmaceutical products.
During the second wave, key market players took major steps as per regulatory guidelines with smart solutions to tackle the supply-demand gap. As of 2021, India shipped over INR 1,349 Bn worth drugs to over 200 nations, ranging from the highly regulated markets in North America and Europe to countries with small pharmaceutical markets.
Competitive insights:
Major players such as Sun Pharmaceuticals Industries Limited, Aurobindo Pharma Limited, Lupin Limited, and Dr. Reddy's Laboratories Limited have made huge strides in their net revenue. This is because of government initiatives that propelled export possibilities.
Key Topics Covered:
Chapter 1: Executive summary
Chapter 2: Socio-economic indicators
Chapter 3: Introduction
3.1. Market definition and structure
Chapter 4: Market overview
4.1. Pharmaceutical export market in India - An overview
4.2. Export of pharmaceutical products (HS Code: 30) (FY 2019 to FY 2022)
4.3. Country-wise export of pharmaceutical products (HS Code: 30)
Chapter 5: COVID-19 impact assessment
5.1. Overview
5.1.1. Positive impact
5.1.2. Negative impact
5.2. Post-pandemic scenario
Chapter 6: Trade analysis
6.1. Export of pharmaceutical products
6.1.1. Commodity-wise export- Based on value
6.1.2. Country-wise export- Based on value
6.1.3. Other exports- Based on value
Chapter 7: Market influencers
7.1. Market drivers
7.2. Market challenges
Chapter 8: Government initiatives
8.1 Government initiatives
Chapter 9: Competitive landscape
9.1. Alkem Laboratories Limited
9.2. Aurobindo Pharma Limited
9.3. Cipla Limited
9.4. Divi's Laboratories Limited
9.5. Dr. Reddy's Laboratories Limited
9.6. Glenmark Pharmaceuticals Limited
9.7. Lupin Limited
9.8. Sun Pharmaceutical Industries Limited
9.9. Torrent Pharmaceuticals Limited
9.10. Zydus Lifesciences Limited
Chapter 10: Recent developments
For more information about this report visit https://www.researchandmarkets.com/r/640cu7
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
